Hepatology Pipeline

At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.

Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.

Disease States

0 Results

Copy Page URL

CHRONIC HEPATITIS B VIRUS INFECTION Phase 1

PAPD5/7 Inhibitor (GSK3965193)

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Go to Resource

HBV Antisense Oligonucleotide (bepirovirsen)^†

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease (B-Kind)

Go to Resource

CHRONIC HEPATITIS B VIRUS INFECTION Phase 2

HBV Antisense Oligonucleotide (bepirovirsen)^†

Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure)

Go to Resource

HBV Antisense Oligonucleotide (bepirovirsen)^† in sequential assignment with daplusiran/tomligisiran^†

A Study of Sequential Therapy with Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living with Chronic Hepatitis B (B-UNITED)

Go to Resource

HBV Antisense Oligonucleotide (bepirovirsen)^†

Study of Bepirovirsen in Participants Living with Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

Go to Resource

CHRONIC HEPATITIS B VIRUS INFECTION Phase 3

HBV Antisense Oligonucleotide (bepirovirsen)^†

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Go to Resource

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

Go to Resource

CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS Phase 3

Ileal Bile Acid Transporter (IBAT) Inhibitor (Linerixibat)

Linerixibat Long-term Safety, and Tolerability Study (LLSAT)

Go to Resource

Metabolic dysfunction-associated steatohepatitis (MASH) Phase 2

HSD17B13 Small Interfering RNA^†

Phase 2b Study of GSK4532990 in Adults With NASH (HORIZON)

Go to Resource

Fibroblast growth factor 21 (FGF21) analog (Efimosfermin alfa)^†

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Go to Resource

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

Go to Resource

Metabolic dysfunction-associated steatohepatitis (MASH) Phase 3

Fibroblast growth factor 21 (FGF21) analog (Efimosfermin alfa)^†

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH (ZENITH-1)

Go to Resource

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH (ZENITH-2)

Go to Resource

Alcohol-Related Liver Disease (ALD) Phase 2

HSD17B13 Small Interfering RNA^†

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared with Placebo in Adult Participants Aged 18 to 65 Years with Alcohol-related Liver Disease (STARLIGHT)

Go to Resource

Use filter to search Pipeline

Disclaimer

This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.

Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.

Footnotes

*in Phase 1/2 Study.

^†In-licence or other alliance relationship with third party